Open Label Extension Study for Continued Safety and Efficacy Evaluation of Azeliragon in Patients With Mild Alzheimer's Disease
Phase of Trial: Phase III
Latest Information Update: 18 Oct 2017
At a glance
- Drugs Azeliragon (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Acronyms STEADFAST-Extension
- Sponsors vTv Therapeutics LLC
- 03 Jan 2017 Status changed from not yet recruiting to recruiting.
- 17 Nov 2016 Planned End Date changed from 1 Jun 2019 to 1 Nov 2020.
- 17 Nov 2016 Planned primary completion date changed from 1 Jun 2019 to 1 Nov 2020.